AstraZeneca PLC has successfully signed the global license agreement with KYM Biosciences Inc. for the development of CMG901, an antibody-drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
Eisai Co., Ltd. and Bliss Biopharmaceutical Co., Ltd. have joined hands to develop BB-1701, an antibody-drug conjugate (ADC). This new drug is expected to have anti-tumor effects on breast, lung, and other solid tumors.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5075
Published Date: Jun 26, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.
The market size of solar updraft towers is anticipated to attain a CAGR of ~2% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc., and other key players.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by drug type, route of administration, distribution channel, end-user, and by region.
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The high costs of the treatment along with the unavailability of a professional and skilled workforce and the lack of awareness regarding the disease are estimated to be the growth hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.